Immune Checkpoints in Sepsis and the Path Toward Precision Immunotherapy

Sepsis remains a leading cause of mortality worldwide, with immune dysfunction serving as a central driver of adverse outcomes. While early hyperinflammation contributes to organ damage, subsequent immunoparalysis characterized by T-cell exhaustion, monocyte deactivation, and impaired pathogen clearance accounts for late deaths and susceptibility to secondary infections. Immune checkpoint molecules have emerged as critical mediators of sepsis-induced immunosuppression. We reviewed current literature on inhibitory checkpoint pathways including PD-1/PD-L1, CTLA-4, TIM-3, LAG-3, TIGIT, and BTLA in sepsis-induced immune dysfunction. Cell-type-specific expression patterns, dual protective and pathological roles of checkpoint signaling depending on timing and tissue context, and convergence with metabolic and epigenetic reprogramming sustaining immunoparalysis were analyzed. Myeloid checkpoints such as CD47-SIRPα and MerTK contributing to innate immune dysfunction were evaluated. Checkpoint molecules exhibit context-dependent roles with protective and pathological effects varying by timing and tissue microenvironment. Monocyte HLA-DR and ferritin were identified as actionable biomarkers for patient phenotyping. The ImmunoSep trial provides proof-of-concept evidence demonstrating improved outcomes with phenotype-guided immunotherapy. Successful translation of checkpoint-based immunotherapies requires precision medicine frameworks matching the right intervention to the right patient at the right time. Combination immunotherapies hold promise when guided by biomarker-driven stratification Hyperinflammation and immunosuppression coexist from sepsis onsetCheckpoint receptors (PD-1, TIM-3, LAG-3, TIGIT) drive T-cell exhaustionmHLA-DR and ferritin enable bedside immune phenotypingMyeloid checkpoints integrate with metabolic-epigenetic reprogrammingPhenotype-guided immunotherapy improves outcomes (ImmunoSep trial) Hyperinflammation and immunosuppression coexist from sepsis onset Checkpoint receptors (PD-1, TIM-3, LAG-3, TIGIT) drive T-cell exhaustion mHLA-DR and ferritin enable bedside immune phenotyping Myeloid checkpoints integrate with metabolic-epigenetic reprogramming Phenotype-guided immunotherapy improves outcomes (ImmunoSep trial) Sepsis happens when an infection spirals out of control, causing the body’s defense system to go haywire and damage its own organs. It kills millions of people every year worldwide. At first, the body overreacts to the infection with too much inflammation. But then something unexpected happens the immune system becomes exhausted and shuts down, leaving patients defenseless against new infections. This review looks at natural “off switches” in our immune system called checkpoints. Normally, these switches prevent our immune cells from attacking healthy tissue. But during sepsis, these switches get stuck in the “off” position, stopping immune cells from doing their job of fighting germs. It’s like having soldiers who refuse to fight because someone keeps telling them to stand down. The good news is that researchers have found ways to release these brakes and wake up the sleeping immune system. A recent major study showed that doctors can improve patient recovery by first testing what’s wrong with each patient’s immune system and then giving them the right treatment for their specific problem. Some patients need medicine to calm down inflammation, while others need drugs to boost their weakened defenses. This personalized approach, giving the right treatment to the right patient at the right time offers real hope for better sepsis care in the future.